Partner im RedaktionsNetzwerk Deutschland
PodcastsWissenschaftHealthcare Perspectives

Healthcare Perspectives

Siemens Healthineers
Healthcare Perspectives
Neueste Episode

Verfügbare Folgen

5 von 25
  • Advancing liver care with non-invasive tests (Part 2)
    Metabolic dysfunction-associated steatotic liver disease (MASLD), also known as fatty liver disease, is a chronic liver condition that affects nearly 1 in 3 people worldwide. It is closely linked to obesity, type 2 diabetes, and metabolic syndrome. Unchecked, it can progress to a more severe form of disease called Metabolic Dysfunction-Associated Steatohepatitis (MASH). Prognosticating the risk of disease progression in MASLD and MASH has traditionally involved liver biopsy, a process that involves removing a tissue sample with a hollow needle and then examining the sample under a microscope to diagnose and stage disease. However, biopsy has many limitations. Additionally, drug development for MASLD and MASH has proceeded slowly in part due to a reliance on liver biopsy to determine drug efficacy.Recently, increasing evidence is suggesting that non-invasive options, for example, imaging examinations along with blood tests that assess likelihood of disease progression such as the Enhanced Liver Fibrosis (ELF) Test, may effectively reduce the need for the more invasive alternative. Key experts in MASLD and MASH share their perspectives about how clinical evidence supports a shift in the way patients with MASLD and MASH could be evaluated in clinical practice and in research.Host Matt Gee, Director of Collaborations and External Engagement at Siemens Healthineers, is joined by Prof. William Rosenberg, Deputy Director of the Institute for Liver and Digestive Health at University College London as well as Dr. Veronica Miller, Director of the Forum for Collaborative Research at the University of California, Berkeley School of Public Health; Dr. Arun Sanyal, Professor of Medicine, Physiology, and Molecular Pathology in the Division of Gastroenterology at Virginia Commonwealth University; and Dr. Michelle Long, International Medical Vice President of Metabolic Dysfunction-Associated Steatohepatitis at Novo Nordisk and Associate Professor in the Section of Gastroenterology and Hepatology at Boston University.What you’ll learn in this episode:Liver biopsy creates several obstacles for patients and has limitationsDrug development faces challenges by the reliance on biopsy as a measure of treatment effectivenessNon-invasive tools may be suitable alternatives to liver biopsy both in clinical practice and in drug developmentConnect with Matt GeeLinkedIn Connect with Veronica MillerLinkedInConnect with William RosenbergLinkedInConnect with Michelle LongLinkedInConnect with Arun SanyalVCU.edu Hosted on Acast. See acast.com/privacy for more information.
    --------  
    28:19
  • Understanding liver health and MASLD (Part 1)
    A reversible liver condition is the fastest growing cause of liver transplantation in Western countries: Metabolic dysfunction-associated steatotic liver disease—or MASLD—affects patients worldwide. It’s characterized by excessive fat accumulation in the liver and can progress into more severe forms of liver disease, potentially resulting in fibrosis, cirrhosis and liver failure.Risk factors for developing liver disease include obesity, insulin resistance, type 2 diabetes, and metabolic syndrome. Genetics, unhealthy dietary habits, and a sedentary lifestyle can also play significant roles in its development. Diagnosis typically involves imaging examinations along with blood tests that assess liver function and rule out other causes of liver disease.Disease management focuses on lifestyle modifications such as diet and exercise, though new medications are now being prescribed to slow and potentially reverse this condition. Regular monitoring of disease progression is also crucial for successful treatment.In this episode, experts in the field of liver disease address the progress happening in the recognition, diagnosis and treatment of the disease. Host Matt Gee, Director of Collaborations and External Engagement at Siemens Healthineers, is joined by Dr. Michelle Long, International Medical Vice President of Metabolic Dysfunction-Associated Steatohepatitis at Novo Nordisk and Director of Clinical Research for the Section of Gastroenterology and Hepatology at Boston University; Dr. Arun Sanyal, Professor of Medicine, Physiology, and Molecular Pathology in the Division of Gastroenterology at Virginia Commonwealth University; and Michael Betel, President and Founder of the Fatty Liver Alliance.What you’ll learn in this episode:One of the biggest obstacles to diagnosing MASLD before it progresses stems from the lack of visibility and awareness of the diseaseMASLD is a reversible disease when caught in timeMASLD is more complex than a patient’s diet or lifestyle—metabolic dysfunction plays a role Non-invasive testing has become an important tool in advancing patient careConnect with Matt GeeLinkedIn Connect with Michelle LongLinkedInConnect with Arun SanyalVCU.eduConnect with Michael BetelLinkedIn Hosted on Acast. See acast.com/privacy for more information.
    --------  
    26:09
  • The future of radiotherapy
    Radiotherapy plays a vital role in cancer treatment. In Europe alone, incidents of cancer are projected to rise around 20% by 2040, mainly due to an increasingly aging population. It’s numbers like these that emphasize the importance of pushing boundaries in radiotherapy. With AI-optimized workflows, it’s possible to speed up treatment planning and ensure highly personalized therapies and technology like auto contouring can protect healthy organs during irradiation by means of AI. This implementation, however, is often met with challenges like staff shortages and inconsistencies with data collection, highlighting the need for more efficient implementation strategies. In this episode, experts in the fields of radiotherapy and cancer treatment address the amazing headway being made in the world of radiotherapy as well as some of the key roles that current technology can play in the future.Host Sasa Mutic, President of Radiation Oncology Solutions at the Varian Business Area of Siemens Healthineers, is joined by Valery Lemmens, a member of the Board of Directors at Maastro Radiotherapy Clinic in the Netherlands and creator of the Dutch Cancer Atlas; as well as Joost Verhoeff, radiation oncologist and professor of radiotherapy at Amsterdam University Medical Center; and Indrin Chetty, Vice Chair and Director of the Division of Medical Physics at Cedars-Sinai in Los Angeles.What you’ll learn in this episode:By using a digital twin, medical professionals can review existing health records and continually compare that information with patient dataWith adaptive radiotherapy, radiation dosages can be tailored to circumstances like tumor size, type, and position and proximity to vital organsThe Dutch Cancer Atlas interprets and publishes data in a context that increases awareness of regional differences in cancer incidentsThe unique role that data plays in the advancement of cancer careThe deep troves of data that already exist within radiotherapy departments can play a key role in the integration of AI into cancer treatmentsWidespread availability of data creates the opportunity for automated treatment planning and outcome predictionConnect with Sasa MuticLinkedIn Connect with Valery LemmensLinkedInConnect with Joost VerhoeffLinkedInIndrin ChettyLinkedIn Hosted on Acast. See acast.com/privacy for more information.
    --------  
    23:50
  • Women’s health: Closing the gender health gap
    With significant disparities in diagnosis, treatment, and funding when compared to men, women’s health has long been underserved. These gaps affect not only individual health outcomes, they also have societal and economic implications which are highlighted by a recent report by the World Economic Forum and The McKinsey Health Institute which addresses a $1 trillion dollar opportunity to improve lives and economies by mitigating these disparities. Factors like societal perception, clinical practice, and financial investment all play an important part in women’s health. Addressing the gender health gap and overcoming issues like the misdiagnosis of diseases in women, increasing women’s representation in clinical trials, and advocating for greater financial investment in women’s health are all crucial steps in building a more equal healthcare system for all. Today, we’re joined by board members of the World Economic Forum’s Global Alliance for Women’s Health to discuss how building a more equitable healthcare system can drive meaningful change, improve healthcare for women, and create access to significant economic potential worldwide.In this episode, host Elisabeth Staudinger, Member of the Managing Board of Siemens Healthineers, is joined by fellow World Economic Forum’s Global Alliance for Women’s Health board members Nadia Fettah, Minister of Economy and Finance for the Government of Morocco and Shyam Bishen, Head of the Centre for Health & Healthcare at the World Economic Forum.What you’ll learn in this episode:Despite living longer, women spend 25% more time in poor health than menWomen are twice as likely to be misdiagnosed after having a heart attack than men. Along with misdiagnosis and premature discharge, female cardiac patients are also less likely to be prescribed secondary prevention measures after experiencing a cardiac eventHow the Global Alliance for Women's Health is pooling together efforts in research, regulation and funding to close the gender healthcare gap Success stories that give hope on the path to healthcare equalityConnect with Elisabeth StaudingerLinkedInConnect with Nadia Fettah LinkedInConnect with Shyam BishenLinkedIn Hosted on Acast. See acast.com/privacy for more information.
    --------  
    22:17
  • Sepsis: Understanding the body's extreme response to infection
    Sepsis, originally known as blood poisoning, is a life-threatening medical emergency. Tune in to learn about the complexities of sepsis diagnosis, the role of lactate and procalcitonin levels, and the global health challenge it poses. Hear from experts and a sepsis survivor about the advancements in identifying and managing this critical condition. Sepsis is the body’s extreme response to an infection. It occurs when a pre-existing infection triggers a chain reaction throughout a person's body. Sepsis can be difficult to diagnose because patients present different symptoms, and their observation can be subjective. According to the Global Sepsis Alliance, the disease contributes to approximately one in five deaths worldwide and in the United States alone; it stands as the leading cause of death in hospitals, leading to one in three hospital fatalities. Compounding these mortality rates is a rise in antibiotic and antimicrobial resistance due to overuse or misuse. Today, we’re joined by experts in the field of diagnostics and critical care as well as a sepsis patient and advocate in order to more acutely understand the disease, its diagnosis, and the advancements in the field.In this episode, host Ranga Sampath, Senior Vice President and Head of the Center for Innovation in Diagnostics at Siemens Healthineers and Member of the Board of the Sepsis Alliance, welcomes:Heike Spreter-Krick a sepsis survivor who is now a patient advocate working with the Global Sepsis AlliancePatti DeJuilio, Director of Respiratory Care and Diagnostic Services at Northwestern Medicine Central DuPage Hospital in Winfield, IllinoisDr. Eric Gluck, Director of Critical Care Services at Swedish Hospital and professor of medicine at Finch University of Health Sciences at The Chicago Medical SchoolMervyn Singer, professor of intensive care medicine at University College London What you’ll learn in this episode:The timing of diagnosis and treatment is critical because sepsis creates oxygen deprivation in the cells.Risk factors like age and comorbidities can increase the likelihood of a patient developing sepsis.The biomarker procalcitonin can be used as an identifier for sepsis infection.Lactate levels, a chemical naturally produced by the body during times of stress, can be used as one indicator among others that a patient may be experiencing sepsis.In the UK, the National Early Warning Score helps closely monitor patients at risk for developing sepsis.IV antibiotics have long been the gold standard for sepsis treatment, but they are at risk of overuse and misuse.For many patients, surviving a sepsis infection is just the beginning of a long road to recovery.Connect with Ranga SampathLinkedInConnect with Heike Spreter-KrickInstagramConnect with Patti DeJuilioLinkedInConnect with Mervyn SingerLinkedIn Hosted on Acast. See acast.com/privacy for more information.
    --------  
    31:32

Weitere Wissenschaft Podcasts

Über Healthcare Perspectives

Healthcare Perspectives is a podcast by Siemens Healthineers about medical breakthroughs with the power to improve the lives of patients and their families everywhere. Meet thought leaders from across the globe, as we discuss our shared vision of fighting the world's most threatening diseases through breakthrough medical technology. Hear how technologies like patient twinning, precision therapy and digitization help medical professionals to make the best possible decisions. Hosted on Acast. See acast.com/privacy for more information.
Podcast-Website

Hören Sie Healthcare Perspectives, Wissen Weekly und viele andere Podcasts aus aller Welt mit der radio.de-App

Hol dir die kostenlose radio.de App

  • Sender und Podcasts favorisieren
  • Streamen via Wifi oder Bluetooth
  • Unterstützt Carplay & Android Auto
  • viele weitere App Funktionen
Rechtliches
Social
v7.18.5 | © 2007-2025 radio.de GmbH
Generated: 6/18/2025 - 12:02:42 AM